We believe evidence is a duty, not a chore

Our digital therapeutics aren’t just based on science: They’ve been proven effective in gold-standard clinical trials.

Setting the standard for rigorous clinical evidence

We believe digital therapeutics must be put to the test as rigorously as traditional medicine. People’s mental health depends on it. That belief not only fuels our commitment to clinical evidence — it also drives our efforts to make research more equitable for underserved populations.




Randomized controlled trials (RCTs)


Study participants


Clinical guideline citations1-4

Sleepio helped 76% of patients achieve clinical improvement in insomnia

In the world’s first placebo-controlled trial for a digital therapeutic, Sleepio was shown to be significantly more effective than the placebo. After six weeks, 76% of Sleepio patients achieved clinical improvement in insomnia.5

Graph depicting the % of patients achieving healthy sleep using Sleepio versus a placebo and versus "treatment as usual."

Daylight helped 71% of patients achieve clinical improvement in anxiety

In a landmark study, Daylight demonstrated significantly greater reductions in symptoms of clinical anxiety than the control condition. After 10 weeks, 71% of Daylight patients moved from clinical to non-clinical levels of anxiety, as compared to 33% of those in the control group.6

Graph depicting levels of anxiety (measured with the GAD-7) from Week 0 to Week 10 for both Daylight users and a waitlist control.

The effects of dCBT for insomnia on cognitive function

Kyle et al. (2020)/SLEEP
Read paper

Efficacy of dCBT for moderate-to-severe symptoms of generalized anxiety disorder

Carl et al. (2020)/Depression & Anxiety
Read paper

A randomized controlled trial of dCBT for insomnia in pregnant women

Kalmbach et al. (2020)/Sleep Medicine
Read paper

Efficacy of dCBT for the treatment of insomnia symptoms among pregnant women

Felder et al. (2020)/JAMA Psychiatry
Read paper

A pilot RCT for dCBT for sub-threshold insomnia

Denis et al. (2019)/Sleep Med
Read paper

Efficacy of dCBT for insomnia to improve depression across demographic groups

Cheng et al. (2019)/Psychological Medicine
Read paper

RCT on impact of dCBT for insomnia on health, wellbeing, and quality of life

Espie et al. (2018)/JAMA Psychiatry
Read paper

The effects of improving sleep on mental health (OASIS)

Freeman et al. (2017)/Lancet Psychiatry
Read paper

Sleep to lower elevated blood pressure (SLEPT)

McGrath et al. (2017)/American Journal of Hypertension
Read paper

Helping employees sleep well: effects of CBT for insomnia on work outcomes

Barnes et al. (2017)/Journal of Applied Psychology
Read paper

Sleep and productivity benefits of digital CBTi

Bostock et al. (2016)/JOEM
Read paper

The anxiolytic effects of cognitive behavior therapy for insomnia

Pillai et al. (2015)/Journal of Sleep Medicine Disorders
Read paper

RCT of placebo controlled dCBT for chronic insomnia disorder

Espie et al. (2012)/SLEEP
Read paper

Disclaimer: In accordance with FDA’s Current Enforcement Discretion Policy for Digital Health Devices for Psychiatric Disorders, for patients aged 18 years and older, who are followed by and diagnosed with Insomnia Disorder or Generalized Anxiety Disorder by a medical provider, Sleepio and Daylight can be made available as an adjunct to their usual medical care for Insomnia Disorder or Generalized Anxiety Disorder, respectively. Sleepio and Daylight do not replace the care of a medical provider or the patient’s medication. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for these indications. Users are directed to not make any changes to their prescribed medication or other type of medical treatment without seeking professional medical advice.

1. Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133.
2. Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., … & Spiegelhalder, K. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675-700.
3. Wilson, S., Anderson, K., Baldwin, D., Dijk, D. J., Espie, A., Espie, C., … & Sharpley, A. (2019). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. Journal of Psychopharmacology, 33(8), 923-947.
4. King’s Technology Evaluation Centre. (2017, November 9). Overview: Health app: SLEEPIO for adults with poor Sleep: Advice. NICE. https://www.nice.org.uk/advice/mib129.
5. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.
6. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and Anxiety, 37(12), 1168-1178.